> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – February 2012

Loading EJC News Focus video

The largest ever screening trial in lung cancer reported last year that screening with low-dose CT reduces mortality from the disease. This impressive trial, from the US’ National Lung Screening Trial Research Team, demonstrated that CT scans could detect both early stage and advanced disease. So – does that mean that lung screening is set to become a reality in many countries? Not in the short term, says EJC’s Lung Cancer Editor, Mary O’Brien (Royal Marsden Hospital, Sutton, Surrey, UK). She told Helen Saul that other ongoing trials will take between 5 and 10 years to report, and that these results will be needed to answer outstanding questions before expensive screening programmes can be considered. But in the meantime, she applauds the trial and says it holds important messages for both clinicians and patients.

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening (N Engl J Med 2011; 365:395-409)